Hisun Pharmaceutical To Temporarily Produce Tamiflu Intermediates
This article was originally published in PharmAsia News
Executive Summary
To guarantee drug supply for influenza prevention and control, China's National Development and Reform Commission has approved Hisun Pharmaceutical to temporarily produce Tamiflu intermediates. Prior to this, only Shanghai Pharmaceutical Group and HEC Group had obtained the local drug production authorization (PharmAsia News, May 11, 2009). Hisun will convert manufacturing facilities of its other drugs to produce Tamiflu intermediates, thus it cannot yet confirm output and cost of the product. The company ascribes the move to its growing R&D and production capacity, as well as the local government's preferential taxation policies for firms that adjust their drug production according to market demand. (Click here for more - Chinese Language)